{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-019507","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.502519+00:00","generated_at":"2026-05-23T06:57:49.109761+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"X4 Pharmaceuticals announces 1-for-30 reverse stock split effective April 28 to regain Nasdaq bid price compliance","bullets":["Reverse stock split at 1-for-30 ratio effective 12:01 a.m. ET on April 28, 2025; shares trade split-adjusted under XFOR.","Outstanding shares reduced from ~173.6M to ~5.8M; no fractional shares issued, cash in lieu.","Split intended to cure Nasdaq minimum bid price deficiency; company received extension to August 11, 2025.","Proportional adjustments made to equity awards, options, and warrants; CUSIP changes to 98420X202."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-019507","json":"https://secwatch.observer/filing/0001628280-25-019507.json","markdown":"https://secwatch.observer/filing/0001628280-25-019507.md","text":"https://secwatch.observer/filing/0001628280-25-019507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025019507/0001628280-25-019507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025019507/xfor-20250424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T06:57:49.109761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f9c317cc88c68f293c166882e6e4a4a7c629163","claim":"X4 Pharmaceuticals, Inc: Filed a certificate of amendment to effect a 1-for-30 reverse stock split of common stock, effective April 28, 2025 (effective 2025-04-28).","evidence_excerpt":"On April 24, 2025, X4 Pharmaceuticals, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025019507/0001628280-25-019507-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-04-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}